HES6: A Cell Adhesion Molecule in Cancer and Other Diseases (G55502)

Target Name: HES6

NCBI ID: G55502

HES6: A Cell Adhesion Molecule in Cancer and Other Diseases

HES6 (HES-6), also known as CD28, is a cell adhesion molecule that plays a critical role in the development and progression of many diseases, including cancer. It is a transmembrane protein that is expressed in a variety of tissues and cells, including epithelial, mesenchymal, and neural cells. HES6 has been identified as a potential drug target and a biomarker for several diseases, including cancer, and is the focus of ongoing research in the laboratory and clinical settings.

HES6 is a member of the immunoglobulin superfamily and is characterized by its extracellular domain, which consists of a constant and variable region. The constant region contains a conserved framework that is involved in the formation of the protein's transmembrane structure, while the variable region contains the majority of the protein's unique features. HES6 is composed of 156 amino acids and has a calculated molecular weight of 19.1 kDa.

HES6 is expressed in a variety of tissues and cells, including epithelial, mesenchymal, and neural cells. It is highly expressed in the skin, where it is involved in the development and maintenance of skin tissue repair and regeneration. HES6 is also expressed in other tissues, including the lungs, gut, liver, and pancreas, and has been shown to play a role in the development and progression of several diseases, including cancer.

One of the key functions of HES6 is its role in cell adhesion. HES6 helps to regulate the movement of cells along the body's surface and helps to maintain the integrity of tissues. It is also involved in the formation of tight junctions, which are a type of cell-cell adhesion that is critical for the development and maintenance of tissues and organs.

In addition to its role in cell adhesion, HES6 has also been shown to play a critical role in the development and progression of several diseases, including cancer. It is has been shown to be involved in the regulation of cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). HES6 has also been shown to promote the growth and survival of cancer cells, making it an attractive target for cancer therapies.

HES6 has also been identified as a potential drug target and a biomarker for several diseases, including cancer. Researchers have shown that inhibiting HES6 can lead to significant improvements in the treatment outcomes of several cancer types, including breast, lung, and ovarian cancer. In addition, studies have also shown that HES6 can be used as a biomarker for cancer, as its expression has been shown to be associated with the development and progression of several diseases.

Overall, HES6 is a complex and important protein that plays a critical role in the development and progression of many diseases. Its role in cell adhesion and its involvement in the regulation of cell proliferation and apoptosis make it an attractive target for therapies for a variety of diseases, including cancer. As research continues to advance, HES6 is likely to emerge as a key player in the development of new treatments for a wide range of diseases.

Protein Name: Hes Family BHLH Transcription Factor 6

Functions: Does not bind DNA itself but suppresses both HES1-mediated N box-dependent transcriptional repression and binding of HES1 to E box sequences. Also suppresses HES1-mediated inhibition of the heterodimer formed by ASCL1/MASH1 and TCF3/E47, allowing ASCL1 and TCF3 to up-regulate transcription in its presence. Promotes cell differentiation (By similarity)

More Common Targets